Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
CKD-MBD increases the risk of osteoporosis and fractures in patients with end-stage of kidney disease (ESKD). However, many of the medications for osteoporosis are restricted in administration due to decreased renal function, and the risk of fractures has not been suppressed in the real world. Once fractured, ADL declines, and the mortality rate increases. Thus, urgent approaches against fracture risk are required in dialysis patients. Denosumab could be expected to improve osteoporosis without clinical restrictions in patients with ESKD.
In the present study, the efficacy and safety of Denosumab in dialysis patients with osteoporosis were evaluated retrospectively. We recruited fourteen maintenance dialysis patients with osteoporosis at Juntendo University Urayasu Hospital. Changes in bone mineral density (BMD) in spine and femoral neck, serum calcium (Ca), TRACP-5b (a marker of bone resorption), bone specific alkaline phosphatase (BAP), and intact PTH levels before and after administration of Denosumab were evaluated. Moreover, changes in calcium levels over time were measured after treatment with Denosumab.
Twelve months after start of Denosumab administration, 75.2% decrease in TRACP-5b was observed (P<0.001) and 6.3% increase in femoral BMD (P<0.001), and 48.3% decrease in BAP. Intact PTH levels increased by 35.9% after six months, however decreased by 16.7% after twelve months. Hypocalcemia caused by Denosumab was suppressed by oral administration of VitD3 preparation from 2 weeks before administration of Denosumab, and maintaining a Ca level of 9.0 mg/dL or higher. Serum Ca levels decreased by an average of 2.0 mg/dL after administration of Denosumab, however, decreased levels of serum calcium intended to recover within 14 days. Thus, none of the patients presented with symptoms of hypocalcemia.
In patients with ESKD, control of CKD-MBD and evaluation of low turnover bone are essential. Combination therapy of Denosumab with oral VitD3 preparation is a treatment option that could be expected to be effective and safe in dialysis patients with osteoporosis. It is important to control corrected serum Ca levels along 9.0 to 9.5 mg/dL with oral VitD3 preparation before administration of Denosumab, especially the first administration.
